Both in Biotechnology
enGene Therapeutics vs Outlook Therapeutics
Over the past year ENGN returned −73.7% and OTLK returned −61.8%; their daily moves had a correlation of 0.06.
ENGN −73.7% OTLK −61.8%Growth of $1, one year, split-adjusted
| Metric | ENGN | OTLK |
|---|---|---|
| Price | $1.72 | $0.4621 |
| Market cap | $115.3M | $112.5M |
| Today | +6.17% | +0.46% |
| 1 month | −4.4% | −19.2% |
| 6 months | −80.6% | +99.4% |
| Year to date | −81.0% | −70.8% |
| 1 year | −75.1% | −64.5% |
| Revenue growth (YoY) | — | −99.4% |
| Gross margin | — | −95.0% |
| Net margin | — | −233554.9% |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $241.0M | -$7.0M |
| Dividend yield | — | — |
| Volatility (60d) | 58.2% | 89.1% |
| Short % of float | 3.4% | 39.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).